
A nationwide Spanish cross‐sectional study was conducted. We included patients with cutaneous reactions within 21 days after any dose of the approved vaccines at the time of the study. After a face to face visit with a dermatologist, information on cutaneous reactions was collected through an online professional survey and clinical photographs were sent by email. Results From February 16 to May 15, 2021, we collected 405 reactions after vaccination with the BNT162b2 , mRNA 1273 and AZD1222 vaccines. Cutaneous reactions were classified as: injection site , urticaria , morbilliform , papulovesicular , pityriasis rosea like and purpuric reactions. Most reactions to the mRNA 1273 vaccine were described in women. Eighty reactions were classified as severe/very severe and 81% required treatment. Most are mild to moderate and self limiting, although severe/very severe reactions are reported...
Like
Save
Share